Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami Journal of Oncology Pharmacy Practice.2026; 32(1): 24. CrossRef
The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi Internal Medicine.2026; 65(11): 1450. CrossRef
Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic Options Hiroki Tai, Asahiro Morishita, Tomoko Tadokoro, Kyoko Oura, Rie Yano, Mai Nakahara, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara Nutrients.2026; 18(3): 494. CrossRef
Quality of life in patients with hepatocellular carcinoma: a bibliometric analysis Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Discover Oncology.2026;[Epub] CrossRef
Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi Journal of Liver Cancer.2026; 26(1): 83. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen Journal of Hematology & Oncology.2024;[Epub] CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Masatoshi Tanaka, Etusko Moriyama, Tomotake Shirono, Kota Takaki, Yu Noda, Masahito Nakano, Mitsutoshi Inoue, Kazuki Tsustumi, Ryoko Kuromatsu, Hironori Koga, Kyoko Higuchi, Taku Journal of Gastroenterology and Hepatology.2023; 38(7): 1140. CrossRef
Correlation between branched-chain amino acids intake and total lymphocyte count in head and neck cancer patients: a cross-sectional study Yosua Yan Kristian, Rahmat Cahyanur, Yohannessa Wulandari, Wina Sinaga, Widjaja Lukito, Findy Prasetyawaty, Wiji Lestari BMC Nutrition.2023;[Epub] CrossRef
The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis. Liver biopsy has been the standard to diagnose NASH. However, there has been strong need for precise and accurate noninvasive tests because of invasiveness and sampling variability of biopsy. Metabolomics has drawn attention as a promising diagnostic methodology in the field of NAFLD, particularly to unravel metabolic alterations which plays relevant roles in the progression of NASH. There have been numerous metabolomics researches to find new biomarker of NASH in the last decade, fueled by the recent advances in the metabolomics methodology. This review briefly covers recent research advances on the lipidomics, amino acids and bile acid metabolomics regarding continuing attempts to discover relevant biomarkers for NASH.
Citations
Citations to this article as recorded by
Machine learning-based discrimination of metabolic dysfunction-associated steatotic liver disease: implications of tryptophan metabolites as potential biomarkers Zhenni Liu, Siying Li, Yaxin Tan, Bingchu Li, Nijiao Qin, Peiting Liu, Fengfan Li, Zhiyang Chen, Ziyang Li, Xing Lyu, Xiangyu Zhang, Zhongyuan Xiang, Min Hu, Qichen Long Clinica Chimica Acta.2027; 594: 122854. CrossRef
Dissecting causal relationships between inflammatory factors, plasma metabolites, and nonalcoholic fatty liver disease: a mediating Mendelian randomization study Dequan Zhong, Shizhan Deng, Yonggan Dong, Yanan Qian, Sudi Zhu, Mengxue Hu, Meng Liu, Kemeng Tan, Heng Tang European Journal of Gastroenterology & Hepatology.2026; 38(4): 422. CrossRef
Chronotype, serum metabolome, and nonalcoholic fatty liver disease in middle-aged and older adults: Association and potential mediation analyses Ming-Jun Hu, Xiao-Min Dong, Xue-Li Wang, Bei Yao, Fu Yu, Dan Su, Lu Li, Yong-Liang Zhang, Xin-Min Chu Experimental Gerontology.2026; 213: 112998. CrossRef
Alisol F 24-acetate attenuated metabolic dysfunction-associated steatohepatitis by targeting the KEAP1/NRF2-mediated macrophage pyroptosis Zhiwu Dong, Keliang Huang, Weiyi Wu, Lianxiang Xing, Ying Zhang, Xin Zhang, Wenwei Yang, Kewen Zhao Chinese Medicine.2026;[Epub] CrossRef
Heat therapy attenuates hepatic lipid accumulation via CSAD-driven metabolic reprogramming of fatty acid oxidation Ang Li, Yaru Dai, Yijun Luo, Ge Liang, Luolan Gui, Xinyi Hu, Xin Li, Dingkun Zhang, Wen Zheng, Lu Zhang, Yuanping Gao, Meng Gong Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.2026; 1871(3): 159722. CrossRef
Xanthine oxidoreductase activity in MASLD: links to lipid metabolism, oxidative stress, and inflammation Yangyang Cen, Zhiyu Pu, Xuanxuan Zi, Shenglin Peng, Ruihan Liu, Bowen Yang, Yanna Fan, Jianjun Yang, Yi Zhao, Yannan Zhang Frontiers in Endocrinology.2026;[Epub] CrossRef
Integrated metabolomics and machine learning identify potential biomarkers and metabolism-related targets for MASLD in older adults Ze Jin, Mengpei Zhu, Ziwen Wang, Lina Xiong, Zhifan Xiong Experimental Gerontology.2026; 215: 113067. CrossRef
Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data Helaina E. Huneault, Pradeep Tiwari, Zachery R. Jarrell, Matthew Ryan Smith, Chih-Yu Chen, Ana Ramirez Tovar, Cristian Sanchez-Torres, Scott Gillespie, Shasha Bai, Rodrigo M. Carrillo-Larco, Ajay K. Jain, Katherine P. Yates, Brent A. Neuschwander-Tetri, J Nature Communications.2026;[Epub] CrossRef
Jiangcaoxiang alleviates hepatic fibrosis through the Nrf2/GPX4 signaling pathway: Elucidated via integrated network pharmacology, multi-omics profiling, and experimental validation Xueqing Huang, Jiaqi Xie, Li Yin, Keli Zhou, Xiaoyu Peng, Shiqi Chen, Jiayue Xu, Hongdao Chen, Dehui Yin, Shouzhong Ren, Ye Zhu Fitoterapia.2026; 191: 107192. CrossRef
Loss of CCDC3 alleviates MAFLD and metabolic aging of mice through enhanced AGXT-associated hepatocyte glycine metabolism Yiwei Zhang, Wenjuan Liao, Hongbing Liu, Shelya X. Zeng, Hua Lu Genes & Diseases.2026; : 102339. CrossRef
Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives Jin Jin, Yang Cheng Metabolites.2026; 16(7): 489. CrossRef
Machine learning-based identification of targeted metabolomic biomarkers for early diagnosis and fibrosis-stage discrimination in metabolic dysfunction-associated steatotic liver disease Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Mahmoud Nazih, Arwa Fadel Flemban, Sabry M. Abdelmegeed, Naglaa Abdelmawgoud Ahmed, Ehab Darwish, Ayman Ahmed Sakr, Yousef M. Abdelgawad, Basma M. Abdelgawad, Inas Moaz, Elaf Abozeid, Hanan M. Bedair Frontiers in Nutrition.2026;[Epub] CrossRef
Molecular mechanism of geniposide against ANIT-induced intrahepatic cholestasis by integrative analysis of transcriptomics and metabolomics Junyi Zhang, Yunting Chen, Guangming Luo, Yangjing Luo Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(1): 765. CrossRef
Integration of network pharmacology, UHPLC-Q exactive orbitrap HRMS technique and metabolomics to elucidate the active ingredients and mechanisms of compound danshen pills in treating hypercholesterolemic rats Shanlan Li, Jin An, Tong Zhang, Guangyun Chen, Zixuan Zhang, Zhuoqian Guo, Ziqi Dai, Xuehao Cheng, Sijin Cheng, Xiaomin Xiong, Nan Wang, Guanghui Jiang, Bing Xu, Haimin Lei Journal of Ethnopharmacology.2025; 336: 118759. CrossRef
Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus Fariba Ahmadizar, Zobair M. Younossi Journal of Clinical Gastroenterology.2025; 59(1): 36. CrossRef
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics Emily Flam, Joel T. Haas, Bart Staels Atherosclerosis.2025; 400: 119054. CrossRef
Species differences of fatty liver diseases: comparisons between human and feline Like Ling, Ruilin Li, Mengqiong Xu, Junjie Zhou, Manli Hu, Xin Zhang, Xiao-Jing Zhang American Journal of Physiology-Endocrinology and Metabolism.2025; 328(1): E46. CrossRef
Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity Laia Bertran, Jordi Capellades, Sonia Abelló, Cristóbal Richart, Anna Di Sessa PLOS ONE.2025; 20(3): e0318557. CrossRef
Mechanistic Study of the Deuterium Effect in Chromatographic Separation for Chemical-Tagging Metabolomics and Its Application to Biomarker Discovery in Metabolic Dysfunction-Associated Steatohepatitis Yugo Akioka, Tomoya Higuchi, Takahiro Takayama, Mayuko Ichimura-Shimizu, Koichi Tsuneyama, Koichi Inoue Analytical Chemistry.2025; 97(16): 8931. CrossRef
Platycodon grandiflorum Attenuates Non‐Alcoholic Fatty Liver Disease in Rats Through Regulating Inflammatory Response via PPARγ and TLR4/NF‐κB Signaling Pathway Ming Dang, Jie Zhang, Run‐Xin Ren, Mao‐Mao Fu, Kang‐Jie Li, Huan‐Qing Gao, Qiao Zhang, Jing Wang, Jing Sun, Xiao‐Fei Zhang, Chang‐Li Wang, Meng‐Meng Zhang, Chong‐Bo Zhao Biomedical Chromatography.2025;[Epub] CrossRef
A plasma metabolome‐derived model predicts severe liver outcomes of nonalcoholic fatty liver disease in the UK Biobank Xiaoqin Xu, Jiang Li, Yanqi Fu, Jie Li, Wenqi Shen, Xiao Tan, Ningjian Wang, Bin Wang, Yingli Lu Diabetes, Obesity and Metabolism.2025; 27(9): 4903. CrossRef
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders Maria-Zinaida Dobre, Bogdana Virgolici, Ruxandra Cioarcă-Nedelcu Current Issues in Molecular Biology.2025; 47(7): 565. CrossRef
Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study Sichang Wang BMC Gastroenterology.2025;[Epub] CrossRef
Mechanism of Quercetin alleviated E. coli K88-induced Liver Injury in Broilers Shuaishuai Zhou, Yuxin Fu, Qinglin Yang, Junhong Liu, Yao Li Poultry Science.2025; 104(11): 105828. CrossRef
Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease Ashraf Abbass Basuni, Dina Sweed, Mohammed Fathey Elgazzar, Ashraf Khalil Egyptian Liver Journal.2024;[Epub] CrossRef
Enhanced hepatic metabolic perturbation of polystyrene nanoplastics by UV irradiation-induced hydroxyl radical generation Shiyu He, Jingran Wang, Lihong Zhou, Zhen Mao, Xiaodan Zhang, Jin Cai, Peili Huang Journal of Environmental Sciences.2024; 142: 259. CrossRef
Amino Acids during Pregnancy and Offspring Cardiovascular–Kidney–Metabolic Health You-Lin Tain, Chien-Ning Hsu Nutrients.2024; 16(9): 1263. CrossRef
Association Between Remnant Cholesterol and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis Jiake Tang, Ting Tang, Qingwen Yu, Xuhan Tong, Chun Liu, Chen Chen, Siqi Hu, Shenghui Zhang, Yao You, Chunyi Wang, Jie Li, Wen Wen, Juan Chen, Xingwei Zhang, Mingwei Wang, Fan Tong Metabolic Syndrome and Related Disorders.2024; 22(9): 637. CrossRef
The Liver-Protective Effects of the Essential Oil from Amomum villosum in Tilapia (Oreochromis niloticus): Antioxidant, Transcriptomic, and Metabolomic Modulations Hongbiao Dong, Xiangbing Zeng, Xiaoting Zheng, Chenghui Li, Junchao Ming, Jiasong Zhang Antioxidants.2024; 13(9): 1118. CrossRef
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics Heng Yuan, Eun-Soo Jung, Soo-Wan Chae, Su-Jin Jung, James W. Daily, Sunmin Park Nutrients.2024; 16(18): 3061. CrossRef
Schisandrin A alleviates non-alcoholic fatty liver disease by improving liver metabolic disorders and suppressing the GSK3β signaling pathway Li Zong, Rui Xu, Yunxia Sun, Junjie Qiu, Huihui Tao, Chengyu Shentu, Hongxia Niu, Tengfei Xu, Yuan Zhou Food Bioscience.2024; 62: 105245. CrossRef
Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro Mahmoud A. Shatta, Marwa O. El-Derany, Abdullah A. Gibriel, Hala O. El-Mesallamy Molecular and Cellular Biochemistry.2023; 478(8): 1689. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study Georgia Anastasiou, Evangelos Liberopoulos, Ermioni Petkou, Amalia Despoina Koutsogianni, Petros Spyridwnas Adamidis, George Liamis, Evangelia Ntzani, Fotios Barkas Diagnostics.2023; 13(3): 503. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and
future Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong Clinical and Molecular Hepatology.2023; 29(Suppl): S171. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young Mice Fed with High Fat and Fructose Diet Wenqing Xiang, Ana Liu, Cuifang Xu, Danni Zhang, Wei Li, Yan Ni Molecular Nutrition & Food Research.2023;[Epub] CrossRef
A lipidomic study: Nobiletin ameliorates hepatic steatosis through regulation of lipid alternation Xushan Yang, Linye Sun, Dongliang Feng, Yudi Deng, Wenzhen Liao The Journal of Nutritional Biochemistry.2023; 118: 109353. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease Metin Demirel, Fatmanur Köktaşoğlu, Esin Özkan, Halime Dulun Ağaç, Ayşe Zehra Gül, Rasul Sharifov, Ufuk Sarıkaya, Metin Başaranoğlu, Şahabettin Selek Scandinavian Journal of Gastroenterology.2023; 58(11): 1344. CrossRef
Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis Xinzhu Liu, Jiaxuan Wang, Maogang Li, Jiannan Qiu, Xingying Li, Li Qi, Jia Liu, Ping Liu, Guoxiang Xie, Xiaoning Wang Journal of Gastroenterology and Hepatology.2023; 38(8): 1438. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim Trials.2023;[Epub] CrossRef
Bavachin combined with epimedin B induce idiosyncratic liver injury under immunological stress conditions Mengmeng Lin, Yingying Li, Bo Cao, Jing Xu, Yujun Zhang, Guohui Li, Xiaohe Xiao, Chunyu Li Chemico-Biological Interactions.2023; 386: 110774. CrossRef
Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD Charalambos Fotakis, Ioanna-Panagiota Kalafati, Athina I. Amanatidou, Vasiliki Andreou, Manolis Matzapetakis, Maria Kafyra, Iraklis Varlamis, Maria Zervou, George V. Dedoussis Frontiers in Endocrinology.2023;[Epub] CrossRef
Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study Jian Zhao, Jing Zeng, Cairong Zhu, Xuechao Li, Dong Liu, Jun Zhang, Fei Li, Giovanni Targher, Jian-Gao Fan BMC Medicine.2023;[Epub] CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim Diagnostics.2022; 12(5): 1199. CrossRef
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology Youngseok Lee, Jong-Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley Current Oncology.2022; 30(1): 48. CrossRef
Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics Yanbo Feng, Han Li, Cong Chen, Hao Lin, Guangyu Xu, He Li, Chunmei Wang, Jianguang Chen, Jinghui Sun Frontiers in Pharmacology.2021;[Epub] CrossRef
First
Prev
